================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) August 18, 2004
HAEMONETICS CORPORATION
--------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Massachusetts 1-10730 04-2882273
---------------------------- ---------------- -------------------
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
400 Wood Road Braintree, MA 02184
---------------------------------------- ----------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (781) 848-7100
--------------------------------------------------------------------------------
(Former name or former address if changed since last report)
================================================================================
Item. 5 OTHER EVENTS AND REGULATION FD DISCLOSURE
On August 18, 2004, Haemonetics Corporation (the "Company")
announced that its Board of Directors has elected Susan Bartlett
Foote and Pedro Granadillo to fill open director seats. The
appointments are effective immediately.
Ms. Foote and Mr. Granadillo will serve on the Compensation and
Management Development Committee of the Board. Mr. Granadillo will
also serve on the Nominating and Governance Committee.
Item. 7 FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits
99.1: Press Release of Haemonetics Corporation dated August
18, 2004
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
(Registrant)
Date: August 18, 2004 By: /s/ Ronald J. Ryan
----------------------------------
Ronald J. Ryan, Vice President and
Chief Financial Officer
2
EXHIBIT INDEX
Exhibit No. Subject Matter
99.1 Press Release of Haemonetics Corporation dated August 18,
2004.
3